Latest News About Replimune Limited

Here’s a concise update on Replimune Limited based on recent public reporting:

• FDA status and regulatory updates: In 2025–2026, Replimune reported a Complete Response Letter (CRL) from the FDA regarding its RP1 BLA in combination with nivolumab for advanced melanoma, prompting the company to reassess pathways (including potential accelerated/alternative routes) and engage with the agency to address design and population heterogeneity concerns. This regulatory hurdle has been a primary driver of strategic and financial planning for the program [sources indicate CRL events and subsequent FDA feedback incidents]. The CRL and related FDA feedback were key inflection points affecting timing and viability of RP1’s approval path [sources indicate CRL events and subsequent FDA feedback incidents].

• Development and trial updates: The company has continued work on IGNYTE-related trials (including RP1+nivolumab and RP2 REVEAL programs) and has explored data support from IGNYTE-3 and other studies to inform potential regulatory submissions, though path forward depends on FDA feedback and potential accelerated approval viability. Corporate updates consistently emphasize ongoing trial activity and data readouts as potential milestones toward any approval pathway [sources mention IGNYTE trials and ongoing presentations].

• Financial/operational context: Replimune has disclosed cash positions and financing arrangements to support operations amid regulatory delays, with market activity often reflecting investor sentiment around FDA decisions and anticipated timelines. Several reports note stock price volatility tied to regulatory news and the potential for future funding as it relates to advancing RP1 and related programs [sources describe financing and market responses to regulatory news].

• Market and investor activity: Following regulatory communications, investors have shown mixed reactions, including volatility in stock price around BLA resubmission acceptances, PDUFA dates, and CRL-related news. Public summaries commonly highlight ongoing corporate updates, potential strategic pivots, and the need for a viable regulatory pathway to progress RP1 toward approval [sources summarize investor response to regulators and milestones].

Illustrative timeline (high-level, non-exhaustive):

• 2025: FDA accepts resubmission discussions; IGNYTE data cited in filings and press materials.
• 2025–2026: FDA issues CRL for RP1/nivolumab; company engages with FDA to define next steps.
• 2026: Corporate updates reference PDUFA-type targets and manufacturing/readiness considerations, with continued trial activity.

If you’d like, I can pull the latest press releases from Replimune’s investor relations site and summarize the exact FDA documents or provide a short timeline of the regulatory milestones with direct quotes. I can also prepare a brief table comparing RP1’s status to typical accelerated approval criteria and what Replimune would need to demonstrate to move forward. Please tell me which format you prefer.